Hederagenin Attenuates Cardiac Remodeling by Targeting Phosphodiesterase <scp>9A</scp>
Our study suggested that HED, as a novel PDE9A inhibitor, ameliorated cardiac hypertrophic response by activating the cGMP-PKG signaling pathway, presenting a potential therapeutic strategy for heart failure.
Authors
- Wen Jin (ORCID: https://orcid.org/0000-0002-2085-4340)
- Yijian Deng
- Baizhao Peng
- Jie Chen (ORCID: https://orcid.org/0000-0003-3435-0351)
- Yue Wang (ORCID: https://orcid.org/0000-0003-0098-5359)
- Ying Liu (ORCID: https://orcid.org/0000-0002-1312-0146)
- Xinyu Zhao (ORCID: https://orcid.org/0000-0002-5128-4424)
- Jieyu Chen (ORCID: https://orcid.org/0000-0002-6254-4324)
- Hiu Yee Kwan
- Lei Zhang
- Ying Yang
- Shuai Ji
- Yanting You
- Huaxi Liu
- Xinghong Zhou
- Liqian Chen
Institutions
- Hong Kong Baptist University (HK)
- Henan University of Traditional Chinese Medicine (CN)
- Nanfang Hospital (CN)
- Guangdong Provincial People's Hospital (CN)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Phytotherapy Research
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1002/ptr.70288
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00